Jonathan P. Terdiman, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jonathan P. Terdiman, MD

Associate Clinical Professor, Department of Medicine (Gastroenterology), UCSF

Phone: (415) 502-4444 (appts)
Box 1623, UCSF
San Francisco, CA 94143-1623

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Cancer Genetics

Education

Princeton University, A.B., cum laude, 1985
Columbia University, College of Physicians and Surgeons, M.D., 1989


Professional Experience

  • 1989-1992
    Resident in Internal Medicine, University of California, San Francisco, San Francisco CA
  • 1992-1993
    Fellow in Critical Care Medicine, University of California, San Francisco, San Francisco, CA
  • 1993-1996
    Fellow in Gastroenterology, University of California, San Francisco, San Francisco, CA
  • 1996-2000
    Staff Physician, Department of Veterans Affairs Medical Center, San Francisco, CA
  • 1996-2002
    Assistant Clinical Professor of Medicine, University of California, San Francisco, San Francisco, CA
  • 1996-present
    Staff Physician, University of California, San Francisco Medical Center, San Francisco, CA
  • 1996-present
    Director of the Colorectal Cancer Prevention Program, UCSF, San Francisco, CA
  • 1998-present
    Clinical Director, Center for Inflammatory Bowel Disease, UCSF, San Francisco, CA
  • 1998-present
    Member, Cancer Center, University of California, San Francisco, San Francisco, CA
  • 1998-present
    Member, Gastrointestinal Oncology Section, American Gastroenterological Society, Bethesda, MD
  • 1999-present
    Member, Colorectal Cancer Initiative Team, American Cancer Society California Division, Oakland, CA
  • 2000-present
    Chair, Abstract Review Committee, GI Oncology Section, AGA, Bethesda, MD
  • 2001-present
    Co-Chair, Crohn's and Colitis Foundation, northern California Chapter, Medical Advisory Board
  • 2002-present
    Associate Professor of Clinical Medicine, University of California, San Francisco, San Francisco, CA
  • 2003-present
    Director, Gastroenterology Fellowship, University of California, San Francisco, San Francisco, CA
  • 2005-present
    Member, Academy of Medical Educators, University of California, San Francisco, SF, CA

Honors & Awards

  • 2000
    UCSF Medical School Class of 2002, Excellence in Small Group Instruction, recipient
  • 2002
    UCSF Medical School Class of 2004, Excellence in Small Group Instruction, recipient
  • 2004
    UCSF Medical School Class of 2006, Excellence in Small Group Instruction, recipient
  • 2005
    Excellence in Direct Teaching, recipient, UCSF Academy of Medical Educators

Selected Publications

  1. Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. Gastroenterology. 2015 Nov; 149(6):1446-53.
    View on PubMed
  2. PMS2 monoallelic mutation carriers: the known unknown. Genet Med. 2016 Jan; 18(1):13-9.
    View on PubMed
  3. Screening for lynch syndrome: it is time to shift the focus. Dig Dis Sci. 2015 Feb; 60(2):586-7.
    View on PubMed
  4. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Jul 10; 371(2):186.
    View on PubMed
  5. Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience. Dig Dis Sci. 2015 Aug; 60(8):2463-9.
    View on PubMed
  6. A workplace colorectal cancer screening program in firefighters: lessons learned. Occup Med (Lond). 2014 Jun; 64(4):255-8.
    View on PubMed
  7. Immunoglobulin therapy for refractory Crohn's disease. Therap Adv Gastroenterol. 2014 Mar; 7(2):99-102.
    View on PubMed
  8. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1459-63.
    View on PubMed
  9. Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. Dig Dis Sci. 2014 Jan; 59(1):135-45.
    View on PubMed
  10. Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol. 2012 Dec; 127(3):544-51.
    View on PubMed
  11. Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer. 2013 Jan 1; 119(1):215-25.
    View on PubMed
  12. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012 Nov; 18(11):2026-33.
    View on PubMed
  13. The impact of the quality of colon preparation on follow-up colonoscopy recommendations. Am J Gastroenterol. 2011 Dec; 106(12):2058-62.
    View on PubMed
  14. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1013-9.
    View on PubMed
  15. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011 Jul 19; 155(2):69-79.
    View on PubMed
  16. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011 Oct; 106(10):1822-7; quiz 1828.
    View on PubMed
  17. The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven. Am J Gastroenterol. 2011 Apr; 106(4):737-40.
    View on PubMed
  18. Screening prevalence and incidence of colorectal cancer among American Indian/Alaskan natives in the Indian Health Service. Dig Dis Sci. 2011 Jul; 56(7):2104-13.
    View on PubMed
  19. Surveillance guidelines should be updated to recognize the importance of serrated polyps. Gastroenterology. 2010 Nov; 139(5):1444-7.
    View on PubMed
  20. Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation. Am J Gastroenterol. 2010 May; 105(5):1210-1.
    View on PubMed

Go to UCSF Profiles, powered by CTSI